COMPARATIVE STUDY OF COMBINATION THERAPY OF TELMISARTAN + AMLODIPINE VS TELMISARTAN + CILNIDIPINE IN HYPERTENSIVE PATIENTS
DOI:
https://doi.org/10.48047/Keywords:
combination therapy, comparative study, aggressive hypertension, cardiovascular endpoints, antihypertensive efficacy.Abstract
BACKGROUND :
Hypertension also known as high blood pressure, is a hidden global menace, and it is a major risk of other heart diseases. A crucial need for any combination is evidence that it reduces BP significantly more than monotherapy with its separate components.
METHOD:
A comparative observational study of combination therapy (Telmisartan + Amlodipine vs Telmisartan + Cilnidipine) in Hypertensive patients was conducted over 6 months in tertiary care hospital, a total of 108 cases were collected and patient’s medical records were assessed.
RESULTS:
The results showed a considerable reduction in blood pressure among both the selected groups. There is a considerable reduction of blood pressure in the group A patients (of about 30mmHg systolic pressure decrease and 20mmHg diastolic pressure decrease) with an exception in some patients, with the incidences of side effects of unusual heart rate, and general puffiness. Group B showed significant results in decreasing the BP levels and also maintaining stability after consecutive months. There is progressive reduction (of about 40mmHg systolic pressure and 20mmHg diastolic pressure decrease) without any substantial side effects.CONCLUSION:
The corresponding study concludes that blood pressure can be significantly decreased and maintained after the discharge of the patients with comparatively fewer incidences of side effects by the antihypertensive combination of Telmisartan + Cilnidipine compared to the combination of Telmisartan + Amlodipine which doesn’t maintain the stable BP and has the incidence of side effects.
